Biotech projects win five R&D Start grants
Friday, 11 March, 2005
Five biotechnology projects were amongst $19 million worth of AusIndustry R&D Start grants announced today by federal industry minister Ian Macfarlane.
The biggest winner was Sydney biotech Gropep (ASX:GRO) which received $3.3 million for the development of PP0102, its topically administered peptide treatment for psoriasis.
Sydney diagnostics company Medsaic will receive $1.5 million towards the development of its platform technology for the diagnosis of blood borne and solid tissue diseases.
Other grants were awarded to:
- Coridon, for a human herpesvirus (HSV) DNA Vaccine ($1.5 million)
- Vital Health Sciences, for a transdermal delivery system for morphine ($1.7 million)
- Plantic Technologies, for the development of high performance biodegradable films for consumer goods applications ($1.7 million)
Tasmania grabs 3 Commercial Ready grants
Three Tasmanian companies are among the very first projects to be awarded funding under the government's new Commercial Ready program. The successful companies were:
- Verdant, which received $1 million to develop new sensing technology to improve understanding and mastering of complex fisheries and aquaculture systems
- Marinova, which received $894,237 to work on a new process for producing high-value bio-therapeutic products from seaweed
- Serve-Ag, which received $500,706 to develop environmental and plant nutrition monitoring products for crop-based agriculture
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Genetics shape our personality and life outcomes more than we thought
Scientists have identified >1200 genetic variants associated with personality traits,...
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
